Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crisaborole Safety in Infants with AD
NCT03356977Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jan 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of AN2728 ointment vehicle in atopic dermatitis (AD), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Site Reactions, Number of Participants With Clinically Significant Height Values Meeting Pre-defined Criteria and 7 more. Started Jan 2018; status: completed.
02
Drugs
AN2728 ointment vehicle
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03356977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356977.